Comparison · NCT00032487-sae
Arm 1 vs Arm 2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 vs Arm 2: serious adverse events. Trial comparisons, record NCT00032487-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00032487-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.16 | 0.138 | 0.186 | wilson | |
| Risk in group 2 | 0.221 | 0.195 | 0.249 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0607 | -0.0969 | -0.0243 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.725 | 0.597 | 0.88 | log | |
| Odds ratio, group 1 over group 2 | 0.673 | 0.53 | 0.854 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm 1 than on Arm 2 | 16.5 | 10.3 | 41.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 | Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs | 144 | 899 | EG000 |
| Group 2 | Arm 2 | Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1 | 197 | 892 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The adverse events were collected in a 82-month period.
Source ClinicalTrials.gov
Trial
- Title
- Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
- NCT number
- NCT00032487
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin, Glimepiride, Rosiglitazone, Metformin
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2014-02-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00032487?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00032487-sae